無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

セファロスポリン剤の世界市場:2015-2019年

Global Cephalosporin Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 340622
出版日 ページ情報 英文 100 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
セファロスポリン剤の世界市場:2015-2019年 Global Cephalosporin Drugs Market 2015-2019
出版日: 2015年09月23日 ページ情報: 英文 100 Pages
概要

世界のセファロスポリン剤の市場は2014年から2019年にかけて3.21%のCAGRで成長すると予測されています。

当レポートでは、世界のセファロスポリン剤市場を調査し、セファロスポリンの開発の経緯と作用機序、抗生剤利用の関する原則、米国における関連法規制、地域による抗生剤利用の動向、セファロスポリン剤の収益規模の推移と予測、世代・経路に関する動向、地域別の収益規模の推移と予測、市場成長への各種影響因子の分析、競合環境と市場シェア、主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 調査範囲

  • 市場概要
  • 主要ベンダーの提供製品

第3章 市場調査手法

  • 調査手法
  • 経済指標

第4章 イントロダクション

  • 市場ハイライト

第5章 セファロスポリンの概要

  • イントロダクション
  • セファロスポリンの先駆物質
  • 作用機序
  • 抗生物質利用の原則
  • 臨床的利用
  • 疫学

第6章 抗生物質の消費:概要

  • ラテンアメリカ
  • 欧州
  • アジア太平洋

第7章 抗生物質の利用に関する法規制:米国

第8章 市場環境

  • 市場概要
  • 市場規模・予測
  • ファイブフォース分析

第9章 市場分析:セファロスポリン世代別

  • 第1世代
  • 第2世代
  • 第3世代
  • 第4世代
  • 第5世代

第10章 市場分析:経路別

  • 注射
  • 経口

第11章 地域分析

  • 世界のセファロスポリン剤市場:地域別
  • 南北アメリカ
  • 欧州
  • アジア太平洋

第12章 市場成長因子

第13章 成長因子の影響

第14章 市場課題

第15章 成長推進因子・課題の影響

第16章 市場動向

第17章 ベンダー環境

  • 競合シナリオ
  • 市場シェア分析
  • 他の有力ベンダー

第18章 主要ベンダーの分析

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

第19章 付録

第20章 Technavioについて

図表

図表
  • Exhibit 01: Product offerings
  • Exhibit 02: Evolution of cephalosporin drugs
  • Exhibit 03: Overview of the activity of different generations of cephalosporin drugs
  • Exhibit 04: General principles involved in use of antibiotics
  • Exhibit 05: Estimated number of cases for nosocomial infections in the US 2011
  • Exhibit 06: Number of cases of E.coli in the UK 2012-2014
  • Exhibit 07: Legislation relating to the use of antibiotics in the US
  • Exhibit 08: Global cephalosporin drugs market 2014-2019 ($ millions)
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Global cephalosporin drugs market segment by generation
  • Exhibit 11: Overview of activity of different generations of cephalosporins
  • Exhibit 12: Evolution of different generations of cephalosporin drugs
  • Exhibit 13: Global cephalosporin drugs market segment by route of administration
  • Exhibit 14: Different generations of cephalosporin drugs by route of administration
  • Exhibit 15: Global cephalosporin drugs market segment by geography 2014
  • Exhibit 16: Global cephalosporin drugs market revenue by geography 2014-2019 ($ millions)
  • Exhibit 17: Cephalosporin drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 18: Percentage share of cephalosporin market in Americas
  • Exhibit 19: Percentage share of market by generation of cephalosporin in the US based on revenue 2014
  • Exhibit 20: Cephalosporin drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 21: Percentage share of cephalosporin drugs market in EMEA
  • Exhibit 22: Percentage share of market by generation of cephalosporin in EU based on revenue 2014
  • Exhibit 23: Cephalosporin drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Cephalosporin resistant strains according to the period of development of resistance
  • Exhibit 26: Impact of drivers and challenges
  • Exhibit 27: Allergan: YoY growth and revenue generated from net product sales of anti-infective drugs 2011-2013 ($ millions)
  • Exhibit 28: Allergan: Key takeaways
  • Exhibit 29: Astellas: Key takeaways
  • Exhibit 30: Bristol-Myers Squibb: Key takeaways
  • Exhibit 31: GSK: Key takeaways
  • Exhibit 32: Merck: Key takeaways
  • Exhibit 33: Pfizer: Key takeaways
  • Exhibit 34: Sandoz: Key takeaways
  • Exhibit 35: Teva Pharmaceuticals: Key takeaways
  • Exhibit 36: Allergan: Business segmentation by product revenue 2014
  • Exhibit 37: Allergan: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Allergan: Geographical segmentation by revenue 2014
  • Exhibit 39: Astellas: Product segmentation by revenue 2015
  • Exhibit 40: Astellas: Product segmentation by revenue 2014 and 2015 ($ billions)
  • Exhibit 41: Astellas: Geographical segmentation by revenue 2015
  • Exhibit 42: Bristol-Myers Squibb: Segmentation by revenue 2014
  • Exhibit 43: Bristol-Myers Squibb: Segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 44: Bristol-Myers Squibb: Geographical segmentation by revenue 2014
  • Exhibit 45: GSK: Business segmentation by revenue 2014
  • Exhibit 46: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 47: GSK: Geographical segmentation by revenue 2014
  • Exhibit 48: Merck: Business segmentation by revenue 2014
  • Exhibit 49: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 50: Merck: Geographical segmentation by revenue 2014
  • Exhibit 51: Pfizer: Business segmentation by revenue 2014
  • Exhibit 52: Pfizer business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 53: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 54: Sandoz: Business segmentation by revenue 2014
  • Exhibit 55: Teva Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 56: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014
  • Exhibit 57: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
目次
Product Code: IRTNTR7550

About cephalosporins

Cephalosporins are bactericidal antibiotics and act by inhibiting cell wall synthesis. They inhibit a wide variety of gram-positive and gram-negative bacteria. They are considered broad-spectrum antibiotics with similar activities to those of ampicillin. They are sometimes grouped into "generations" by their antimicrobial properties. Cephalosporin drugs can be grouped into five classes or generations. The gram-negative antimicrobial property significantly increases with each newer generation of cephalosporin.

Technavio's analysts forecast the global cephalosporin drugs market to grow at a CAGR of 3.21% over the period 2014-2019.

Covered in this report

In this report, Technavio covers the present scenario and growth prospects of the global cephalosporin drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various prescription drugs along with the generic drugs used for the treatment of various infectious diseases caused by the different strains of bacteria.

Technavio's report, Global Cephalosporin Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global cephalosporin drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Aspen Pharmacare
  • AstraZeneca
  • Aurobindo Pharma
  • Basilea Pharmaceuticals
  • Baxter
  • Biocon
  • Corden Pharma
  • Cornerstone Therapeutics
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Flynn Pharma
  • Hospira
  • Incepta Pharmaceuticals
  • Johnson & Johnson
  • Kyorin Pharmaceutical
  • Lupin Pharmaceuticals
  • Orchid Pharma
  • Par Pharmaceutical
  • Pernix Therapeutics
  • Sanofi
  • Shionogi
  • Sun Pharmaceutical
  • Takeda Pharma
  • Theravance Biopharma
  • Wockhardt

Market driver

  • Special regulatory designation for pipeline molecules
  • For a full, detailed list, view our report

Market challenge

  • Development of drug resistance
  • For a full, detailed list, view our report

Market trend

  • Use of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Cephalosporin overview

  • Introduction
  • Precursors of cephalosporins
  • Mechanism of action
  • General principles for use of antibiotics
  • Clinical uses
  • Epidemiology

PART 06: Overview on the consumption of antibiotics

  • Latin America
  • Europe
  • APAC

PART 07: Legislation relating to antibiotic use in the US

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by generation of cephalosporin

  • First-generation cephalosporins
  • Second-generation cephalosporins
  • Third-generation cephalosporins
  • Fourth-generation cephalosporins
  • Fifth-generation cephalosporins

PART 10: Market segmentation by route of administration

  • Injection
  • Oral

PART 11: Geographical segmentation

  • Segmentation of global cephalosporin drugs market by geography
  • Cephalosporin drugs market in Americas
  • Cephalosporin drugs market in EMEA
  • Cephalosporin drugs market in APAC

PART 12: Market drivers

  • Special regulatory designation for pipeline molecules
  • Rise in prevalence of infectious diseases
  • Increase in awareness

PART 13: Impact of drivers

PART 14: Market challenges

  • Development of drug resistance
  • High generic penetration
  • Weak pipeline

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Use of combination therapies
  • Increase in M&A
  • Increasing irrational use of cephalosporins

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Allergan
  • Astellas
  • Bristol-Myers Squibb
  • GSK
  • Merck
  • Pfizer
  • Sandoz
  • Teva Pharmaceuticals

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

Back to Top